Evidence map›Paper›PMID 40430463›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

3-(3-Azabicyclo[2, 2, 1]heptan-2-yl)-1,2,4-oxadiazoles as Novel Potent DPP-4 Inhibitors to Treat T2DM.

Tatiana V Zinevich, Ivan O Maslov, Olga G Kirichenko, Sergey V Shorshnev, Maxim A Gureev, Fedor M Dolgushin, Yuri B Porozov, Vladimir M Trukhan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tatiana V ZinevichDepartment of Bioorganic Chemistry, Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-8391-8823
Ivan O MaslovDepartment of Bioorganic Chemistry, Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-2322-3819
Olga G KirichenkoLLC Institute of Mitoengineering MSU, 119899 Moscow, Russia.
Sergey V ShorshnevMIREA, Russian Technological University, Campus in Malaya Pirogovskaya Street, 119435 Moscow, Russia.
Maxim A GureevLaboratory of Bio- and Chemoinformatics, HSE University, 16 Soyuza Pechatnikov, 190121 Saint-Petersburg, Russia.ORCID 0000-0002-0385-922X
Fedor M DolgushinKurnakov Institute of General and Inorganic Chemistry RAS, 119071 Moscow, Russia.
Yuri B PorozovLaboratory of Bio- and Chemoinformatics, HSE University, 16 Soyuza Pechatnikov, 190121 Saint-Petersburg, Russia.ORCID 0000-0002-5450-3135
Vladimir M TrukhanInstitute for Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-4726-333X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DPP-4 inhibitorsmolecular dockingoxadiazolesstereoisomerismstructure–activity relationshiptype 2 diabetes mellitus

Identifiers

PMID40430463
PMCPMC12114571

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.